311 A.3d 773
Del.2023Background
- AmerisourceBergen Corporation (ABC), a major distributor in the U.S. pharmaceutical market, incurred over $6 billion in liability as part of a 2021 nationwide opioid settlement.
- Plaintiffs, stockholders of ABC, filed a derivative action alleging the board and officers failed to implement or oversee adequate controls to prevent unlawful opioid distribution, violating their fiduciary duties under Delaware law (Caremark claims).
- Plaintiffs advanced two theories: (1) the board knowingly fostered a culture prioritizing profits over compliance (Massey theory), and (2) the board failed to respond to a plethora of “red flags” indicating noncompliance (Red-Flags theory).
- The defendants moved to dismiss, arguing the company had compliant systems and responded appropriately, and that demand on the board was not futile.
- The Court of Chancery dismissed the case, relying heavily on findings from a federal court decision in West Virginia that found ABC had complied with anti-diversion obligations, negating plaintiffs’ allegations.
- On appeal, the Delaware Supreme Court addressed whether the lower court’s reliance on the West Virginia Decision (post-complaint, non-preclusive factual findings) was consistent with Delaware rules and whether the complaint otherwise stated a claim.
Issues
| Issue | Plaintiff’s Argument | Defendant’s Argument | Held |
|---|---|---|---|
| Whether court could rely on factual findings from another court (West Virginia Decision) to dismiss complaint | Chancery erred by treating adjudicative facts in another court’s opinion as dispositive at the pleading stage. | Reliance proper under D.R.E. 202 as judicial notice of law; findings persuasive, if not preclusive. | Reliance was legal error; findings of fact from another case cannot be judicially noticed as law or used to rebut well-pleaded allegations. |
| Whether derivative complaint adequately pleaded demand futility (substantial likelihood of director liability) | Facts support inference that majority of board faced substantial risk of liability under Caremark/Massey due to ignoring red flags. | Board acted properly, relied on experts, and there were no findings of illegality/admissions; low reporting percentages do not show bad faith. | Complaint pleaded demand futility; sufficient particularized facts suggesting conscious disregard for compliance duties. |
| Whether new developments (DOJ complaint) should affect demand futility analysis | DOJ complaint is newly discovered, material evidence supporting inference of noncompliance. | DOJ complaint cumulative, does not change outcome; demand futility analysis date not shifted. | DOJ complaint immaterial to the outcome; but court erred in using post-complaint findings from WV case to alter demand analysis timing. |
| Whether the Chancery correctly applied Caremark/Massey liability standards to the pleaded facts | Well-pleaded facts and inferences show conscious failure to address systemic legal compliance failures amid numerous red flags. | Caremark liability not adequately alleged; board responded to issues, followed expert advice, and no clear violations. | Complaint satisfied Caremark standard for pleading—well-pleaded allegations and reasonable inferences were sufficient to survive dismissal. |
Key Cases Cited
- Stone v. Ritter, 911 A.2d 362 (Del. 2006) (clarifying requirements for director oversight liability under Caremark)
- In re Walt Disney Co. Derivative Litig., 906 A.2d 27 (Del. 2006) (defining bad faith and the duty of loyalty)
- Marchand v. Barnhill, 212 A.3d 805 (Del. 2019) (board oversight duties and Caremark claims)
- Brehm v. Eisner, 746 A.2d 244 (Del. 2000) (standards for Rule 23.1 pleading and inferences)
- Rales v. Blasband, 634 A.2d 927 (Del. 1993) (demand futility analysis for derivative actions)
- United Food & Com. Workers Union v. Zuckerberg, 262 A.3d 1034 (Del. 2021) (current guidance on demand futility)